These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 33084340)

  • 1. The COVID-19 Pandemic from a Human Genetic Perspective.
    Zhang YM; Wang L; Liu XZ; Zhang H
    J Proteome Res; 2020 Nov; 19(11):4374-4379. PubMed ID: 33084340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission.
    Godri Pollitt KJ; Peccia J; Ko AI; Kaminski N; Dela Cruz CS; Nebert DW; Reichardt JKV; Thompson DC; Vasiliou V
    Hum Genomics; 2020 May; 14(1):17. PubMed ID: 32398162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
    Patil AM; Göthert JR; Khairnar V
    Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of host genetics in susceptibility to severe viral infections in humans and insights into host genetics of severe COVID-19: A systematic review.
    Elhabyan A; Elyaacoub S; Sanad E; Abukhadra A; Elhabyan A; Dinu V
    Virus Res; 2020 Nov; 289():198163. PubMed ID: 32918943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology and treatment strategies for COVID-19.
    Kumar M; Al Khodor S
    J Transl Med; 2020 Sep; 18(1):353. PubMed ID: 32933536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status.
    Bchetnia M; Girard C; Duchaine C; Laprise C
    J Infect Public Health; 2020 Nov; 13(11):1601-1610. PubMed ID: 32778421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2.
    Tutuncuoglu B; Cakir M; Batra J; Bouhaddou M; Eckhardt M; Gordon DE; Krogan NJ
    Cancer Discov; 2020 Jul; 10(7):916-921. PubMed ID: 32444466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China.
    Chu J; Yang N; Wei Y; Yue H; Zhang F; Zhao J; He L; Sheng G; Chen P; Li G; Wu S; Zhang B; Zhang S; Wang C; Miao X; Li J; Liu W; Zhang H
    J Med Virol; 2020 Jul; 92(7):807-813. PubMed ID: 32222986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responding to Covid-19 - A Once-in-a-Century Pandemic?
    Gates B
    N Engl J Med; 2020 Apr; 382(18):1677-1679. PubMed ID: 32109012
    [No Abstract]   [Full Text] [Related]  

  • 13. Approaches and advances in the development of potential therapeutic targets and antiviral agents for the management of SARS-CoV-2 infection.
    Krishna G; Pillai VS; Veettil MV
    Eur J Pharmacol; 2020 Oct; 885():173450. PubMed ID: 32739174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel zoonotic COVID-19 pandemic: An expected global health concern.
    Contini C; Di Nuzzo M; Barp N; Bonazza A; De Giorgio R; Tognon M; Rubino S
    J Infect Dev Ctries; 2020 Mar; 14(3):254-264. PubMed ID: 32235085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2.
    Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY
    Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 17. Potential Antiviral Drugs for SARS-Cov-2 Treatment: Preclinical Findings and Ongoing Clinical Research.
    Bimonte S; Crispo A; Amore A; Celentano E; Cuomo A; Cascella M
    In Vivo; 2020 Jun; 34(3 Suppl):1597-1602. PubMed ID: 32503817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Proteases for Treating COVID-19.
    Luan B; Huynh T; Cheng X; Lan G; Wang HR
    J Proteome Res; 2020 Nov; 19(11):4316-4326. PubMed ID: 33090793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of host genetic variations on response to, susceptibility and severity of respiratory infections.
    Ghafouri-Fard S; Noroozi R; Vafaee R; Branicki W; Poṡpiech E; Pyrc K; Łabaj PP; Omrani MD; Taheri M; Sanak M
    Biomed Pharmacother; 2020 Aug; 128():110296. PubMed ID: 32480226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.